NRx Pharmaceuticals Initiates First Commercial Order for Preservative-Free Ketamine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy NRXP?
NRx Pharmaceuticals announced the initiation of its first commercial manufacturing order of its preservative-free ketamine product in anticipation of approval in Summer 2026. "NRx thanks its manufacturing partner for the care and support that has been invested in this project and looks forward to being able to serve Americans with a safe and convenient US-made ketamine product," said Jonathan Javitt, chairman and CEO of NRx Pharmaceuticals. The order is based on stability observed in more than three manufactured registration batches and the company's successful third-party audit of the manufacturing facility. NRx expects the initial manufacturing pace will be sufficient to support initial substantial yearly revenues and notes the ability to rapidly scale manufacturing as demand grows. The product is the first U.S.-manufactured preservative-free ketamine presentation, utilizing a blow-fill-seal process that achieves more than 10-fold higher manufacturing throughput than traditional sterile bottling techniques.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRXP
Wall Street analysts forecast NRXP stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.060
Low
25.00
Averages
37.67
High
48.00
Current: 3.060
Low
25.00
Averages
37.67
High
48.00
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NRx Pharmaceuticals Receives FDA Clearance for Depression Clinical Trial
- Clinical Trial Launch: NRx Pharmaceuticals has received FDA clearance to conduct a trial of NRX-101 (D-cycloserine/lurasidone fixed-dose combination) against placebo at a leading US academic hospital and three HOPE Therapeutics clinics, targeting enrollment of 400 patients, indicating significant progress in the field of depression treatment.
- Innovative Study Design: The trial is a randomized, double-blind, three-arm study aimed at evaluating NRX-101 as an adjunctive therapy to TMS, and if successful, it could provide an effective non-invasive treatment for military and first responders, enhancing their readiness.
- Funding Strategy: The company plans to support the trial through non-dilutive funding, reflecting NRx's commitment to effective short-term depression treatments, particularly in military and emergency organizations, which could positively impact national health.
- Strong Leadership Team: The trial will be led by Dr. Dennis K. McBride, President of NRx Defense Systems, whose extensive experience at the Defense Advanced Research Projects Agency will provide robust support for the project's successful implementation, further enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Highlights from New to The Street Broadcast
- Rich Program Content: Tonight's episode #746 of New to The Street will air on Bloomberg Television, reaching millions of households across the U.S., MENA, and Latin America, showcasing innovations and developments from various companies.
- Industry Leaders Speak: Dr. Jonathan C. Javitt, CEO of NRx Pharmaceuticals, discusses the company's innovative pipeline in critical care and neuropsychiatric treatments, emphasizing its leading position in the healthcare sector.
- Digital Transformation: Performance Golf, a leading digital golf instruction platform, is transforming how players improve their game worldwide, demonstrating the potential of technology in traditional sports.
- Diverse Sponsorships: The program is further supported by commercial sponsorships from Medicus Pharma, IGC Pharma, Roadzen, and Lantern Pharma, enhancing its influence in the healthcare, AI, and technology sectors.
See More
NRx Receives Positive FDA Review Letter for Ketamine ANDA
- Positive Review Letter: NRx has received a positive Discipline Review Letter from the FDA, requesting only minor administrative changes, indicating favorable feedback on its ANDA application and potentially accelerating the drug's market entry to meet demand for preservative-free ketamine.
- Supportive FDA Meeting: A meeting with leadership from the FDA Office of Generic Drugs confirmed support for the expedited approval of ketamine, particularly under the President's April 16, 2026 Executive Order, which prioritizes drugs for severe depression and suicidality, with potential approval targeted for Summer 2026.
- Urgent Drug Demand: The ANDA application is critical due to the rising clinical demand for preservative-free ketamine, with FDA leadership expressing commitment to prioritize remaining aspects of the application to address supply shortages faced by physicians, ensuring timely access to treatment for patients.
- Strategic Development Direction: NRx is in the process of submitting a New Drug Application to align ketamine labeling with its use in treating depression and suicidality, a move that not only meets FDA policy requirements but also strengthens NRx's market position in the mental health sector.
See More
NRx Receives Preliminary Label Alignment from FDA for Ketamine Product
- FDA Preliminary Feedback: NRx received a letter from the FDA indicating preliminary alignment on the labeling for its preservative-free ketamine product, which remains subject to final supervisory review, laying the groundwork for market entry and potentially enhancing supply.
- Bioequivalence Confirmation: The company previously received a preliminary determination of bioequivalence for this product, indicating comparable efficacy and safety to existing products, which is expected to bolster trust among physicians and patients, thereby driving sales growth.
- Market Demand Opportunity: With multiple ketamine suppliers facing backorders, NRx's product has the potential to significantly augment the supply of US-manufactured ketamine, addressing the increasing market demand for this drug, which holds substantial strategic significance.
- Future Development Plans: NRx is also preparing to submit a New Drug Application under Fast Track Designation for intravenous ketamine to expand its use in patients with severe depression, demonstrating the company's ongoing innovation and intent to expand its market presence in mental health.
See More
NRx Pharmaceuticals Receives FDA Preliminary Label Alignment
- FDA Preliminary Feedback: NRx Pharmaceuticals received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine product, which, while still subject to final review, marks a significant milestone in the drug registration process.
- Bioequivalence Confirmation: The company previously received a preliminary determination of bioequivalence for this product, with an anticipated decision on approval under the Generic Drug User Fee Act (GDUFA) expected in Summer 2026, potentially opening new market opportunities for NRx.
- Market Demand Response: NRx's preservative-free ketamine product is manufactured in the U.S. at a time when multiple suppliers are facing backorders, which is expected to significantly enhance the supply of ketamine in the U.S. market to meet rising medical demand.
- New Drug Application Preparation: In addition to the ANDA application, NRx is preparing a Fast Track New Drug Application for intravenous ketamine to expand its use in patients with severe depression, indicating the company's strategic focus on the mental health sector.
See More
Analysis of NRx Pharmaceuticals' Cash Burn and Market Outlook
- Cash Burn Situation: As of December 2025, NRx Pharmaceuticals had cash reserves of $7.8 million and a cash burn of $14 million over the past year, indicating a cash runway of approximately seven months, although analysts expect the company to break even before then.
- Increasing Cash Burn: The company's cash burn rate increased by 33% in the last year, suggesting that NRx Pharmaceuticals is ramping up investments in its business, which may shorten its cash runway but could also lay the groundwork for future growth.
- Financing Capability Analysis: NRx Pharmaceuticals' cash burn represents 20% of its $72 million market capitalization, indicating that the company could raise additional funds to cover future cash burn without significant difficulty, albeit at the cost of some shareholder dilution.
- Market Outlook: While the cash runway raises concerns, analysts forecast that NRx Pharmaceuticals will achieve breakeven soon, providing some reassurance to shareholders, although potential risk signals should still be monitored.
See More
NRx Pharmaceuticals Receives FDA Clearance for Depression Clinical Trial
- Clinical Trial Launch: NRx Pharmaceuticals has received FDA clearance to conduct a trial of NRX-101 (D-cycloserine/lurasidone fixed-dose combination) against placebo at a leading US academic hospital and three HOPE Therapeutics clinics, targeting enrollment of 400 patients, indicating significant progress in the field of depression treatment.
- Innovative Study Design: The trial is a randomized, double-blind, three-arm study aimed at evaluating NRX-101 as an adjunctive therapy to TMS, and if successful, it could provide an effective non-invasive treatment for military and first responders, enhancing their readiness.
- Funding Strategy: The company plans to support the trial through non-dilutive funding, reflecting NRx's commitment to effective short-term depression treatments, particularly in military and emergency organizations, which could positively impact national health.
- Strong Leadership Team: The trial will be led by Dr. Dennis K. McBride, President of NRx Defense Systems, whose extensive experience at the Defense Advanced Research Projects Agency will provide robust support for the project's successful implementation, further enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Highlights from New to The Street Broadcast
- Rich Program Content: Tonight's episode #746 of New to The Street will air on Bloomberg Television, reaching millions of households across the U.S., MENA, and Latin America, showcasing innovations and developments from various companies.
- Industry Leaders Speak: Dr. Jonathan C. Javitt, CEO of NRx Pharmaceuticals, discusses the company's innovative pipeline in critical care and neuropsychiatric treatments, emphasizing its leading position in the healthcare sector.
- Digital Transformation: Performance Golf, a leading digital golf instruction platform, is transforming how players improve their game worldwide, demonstrating the potential of technology in traditional sports.
- Diverse Sponsorships: The program is further supported by commercial sponsorships from Medicus Pharma, IGC Pharma, Roadzen, and Lantern Pharma, enhancing its influence in the healthcare, AI, and technology sectors.
See More
NRx Receives Positive FDA Review Letter for Ketamine ANDA
- Positive Review Letter: NRx has received a positive Discipline Review Letter from the FDA, requesting only minor administrative changes, indicating favorable feedback on its ANDA application and potentially accelerating the drug's market entry to meet demand for preservative-free ketamine.
- Supportive FDA Meeting: A meeting with leadership from the FDA Office of Generic Drugs confirmed support for the expedited approval of ketamine, particularly under the President's April 16, 2026 Executive Order, which prioritizes drugs for severe depression and suicidality, with potential approval targeted for Summer 2026.
- Urgent Drug Demand: The ANDA application is critical due to the rising clinical demand for preservative-free ketamine, with FDA leadership expressing commitment to prioritize remaining aspects of the application to address supply shortages faced by physicians, ensuring timely access to treatment for patients.
- Strategic Development Direction: NRx is in the process of submitting a New Drug Application to align ketamine labeling with its use in treating depression and suicidality, a move that not only meets FDA policy requirements but also strengthens NRx's market position in the mental health sector.
See More
NRx Receives Preliminary Label Alignment from FDA for Ketamine Product
- FDA Preliminary Feedback: NRx received a letter from the FDA indicating preliminary alignment on the labeling for its preservative-free ketamine product, which remains subject to final supervisory review, laying the groundwork for market entry and potentially enhancing supply.
- Bioequivalence Confirmation: The company previously received a preliminary determination of bioequivalence for this product, indicating comparable efficacy and safety to existing products, which is expected to bolster trust among physicians and patients, thereby driving sales growth.
- Market Demand Opportunity: With multiple ketamine suppliers facing backorders, NRx's product has the potential to significantly augment the supply of US-manufactured ketamine, addressing the increasing market demand for this drug, which holds substantial strategic significance.
- Future Development Plans: NRx is also preparing to submit a New Drug Application under Fast Track Designation for intravenous ketamine to expand its use in patients with severe depression, demonstrating the company's ongoing innovation and intent to expand its market presence in mental health.
See More
NRx Pharmaceuticals Receives FDA Preliminary Label Alignment
- FDA Preliminary Feedback: NRx Pharmaceuticals received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine product, which, while still subject to final review, marks a significant milestone in the drug registration process.
- Bioequivalence Confirmation: The company previously received a preliminary determination of bioequivalence for this product, with an anticipated decision on approval under the Generic Drug User Fee Act (GDUFA) expected in Summer 2026, potentially opening new market opportunities for NRx.
- Market Demand Response: NRx's preservative-free ketamine product is manufactured in the U.S. at a time when multiple suppliers are facing backorders, which is expected to significantly enhance the supply of ketamine in the U.S. market to meet rising medical demand.
- New Drug Application Preparation: In addition to the ANDA application, NRx is preparing a Fast Track New Drug Application for intravenous ketamine to expand its use in patients with severe depression, indicating the company's strategic focus on the mental health sector.
See More
Analysis of NRx Pharmaceuticals' Cash Burn and Market Outlook
- Cash Burn Situation: As of December 2025, NRx Pharmaceuticals had cash reserves of $7.8 million and a cash burn of $14 million over the past year, indicating a cash runway of approximately seven months, although analysts expect the company to break even before then.
- Increasing Cash Burn: The company's cash burn rate increased by 33% in the last year, suggesting that NRx Pharmaceuticals is ramping up investments in its business, which may shorten its cash runway but could also lay the groundwork for future growth.
- Financing Capability Analysis: NRx Pharmaceuticals' cash burn represents 20% of its $72 million market capitalization, indicating that the company could raise additional funds to cover future cash burn without significant difficulty, albeit at the cost of some shareholder dilution.
- Market Outlook: While the cash runway raises concerns, analysts forecast that NRx Pharmaceuticals will achieve breakeven soon, providing some reassurance to shareholders, although potential risk signals should still be monitored.
See More
